Wren is at the forefront of transforming cancer diagnostics through advanced mRNA technologies. Our pioneering machine learning-based liquid biopsy tests utilize multiplex mRNA expression to revolutionize cancer patient care and enhance clinical trials. Conducted in a CLIA-certified, CAP-accredited, and NYSDOH-licensed laboratory, our tests are governed by a robust quality management system.
Our NETest® and PROSTest® assays are clinically validated as diagnostic and prognostic tools, for detecting minimal residual disease and recurrence, and for predicting responses to radiotherapeutics in neuroendocrine and prostate cancers. These clinical assays, featuring binary readouts, are suited for patient selection and stratification in clinical trials, serving as companion or complementary diagnostics. Their utility extends beyond oncology: the FDA has recently accepted our NETest® for predicting tumorigenesis in a diabetic drug trial, addressing potential pancreatic neuroendocrine differentiation.
Wren’s innovative pipeline includes assays for colorectal, lung, breast, pancreatic, melanoma, and multiple myeloma cancers. Our theranostic applications offer customized multigene mRNA gene signatures for biomarker and target discovery, POC, POM, or pharmacodynamics.
Led by a team of biopharma experts with unparalleled scientific, clinical, operational, and regulatory experience, Wren is dedicated to delivering best-in-class services where every sample counts.
www.wrenlaboratories.com
